The NCPE currently have a vacancy for the post of Health Technology Assessor. Please click here for further information.
Version 2.0 of this template replaces version 1.5. Rapid review submissions using version 1.5 will not be accepted after 31 March 2021. Please send the completed form by email to ncpe@stjames.ie.
Latest Updates…
The NCPE recommends that pembrolizumab in combination with axitinib not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments.*
The NCPE recommends that tafamidis not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*.
The NCPE recommends that atezolizumab in combination with carboplatin and etoposide for the first-line treatment of adult patients with ES-SCLC is not considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*.
The NCPE recommends that voretigene neparvovec (Luxturna®) is not considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments.*
The NCPE recommends that talazoparib (Talzenna®) not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*.
Chronic migraine: The NCPE recommends that fremanezumab (Ajovy®), for the prophylaxis of migraine in adult patients with chronic migraine who have failed three or more migraine-preventive treatments, be considered for reimbursement. *
Episodic migraine: The NCPE recommends that fremanezumab (Ajovy®), for the prophylaxis of migraine in adult patients with episodic migraine who have failed three or more migraine-preventive treatments, be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments. *
The NCPE recommends that atezolizumab (Tecentriq®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*.